These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19291011)

  • 21. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
    Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
    Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
    Ferenci P; Laferl H; Scherzer TM; Maieron A; Hofer H; Stauber R; Gschwantler M; Brunner H; Wenisch C; Bischof M; Strasser M; Datz C; Vogel W; Löschenberger K; Steindl-Munda P;
    Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Akhan SC; Kalender B; Ruzgar M
    Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
    Kim CH; Park BD; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS; Lee JI
    Korean J Hepatol; 2009 Mar; 15(1):70-9. PubMed ID: 19346787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial.
    Reimer J; Schmidt CS; Schulte B; Gansefort D; Gölz J; Gerken G; Scherbaum N; Verthein U; Backmund M
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S97-104. PubMed ID: 23884073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
    Lang JP; Melin P; Ouzan D; Rotily M; Fontanges T; Marcellin P; Chousterman M; Cacoub P;
    Antivir Ther; 2010; 15(4):599-606. PubMed ID: 20587853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-α-2b and ribavirin.
    Phillips FH; Prebis M; Grumbeck C; Hale T; Cubillas R; Brown GR
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1435-42. PubMed ID: 20802340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are viral or host factors predictive of response to interferon-ribavirin in transplant patients with hepatitis C?
    Roche B; Samuel D
    J Hepatol; 2010 May; 52(5):630-2. PubMed ID: 20334948
    [No Abstract]   [Full Text] [Related]  

  • 37. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
    Bruce RD; Eiserman J; Acosta A; Gote C; Lim JK; Altice FL
    Am J Drug Alcohol Abuse; 2012 May; 38(3):206-12. PubMed ID: 22242700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
    Silva C; Ianna E; Jones T; Davis JS
    Hepatology; 2015 Aug; 62(2):660-1. PubMed ID: 25380552
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of hepatitis C infection for current or former substance abusers in a community setting.
    John-Baptiste A; Varenbut M; Lingley M; Nedd-Roderique T; Teplin D; Tomlinson G; Daiter J; Krahn M
    J Viral Hepat; 2009 Aug; 16(8):557-67. PubMed ID: 19243498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men.
    Cotte L; Chevallier Queyron P; Schlienger I; Trabaud MA; Brochier C; André P; Zoulim F
    Gastroenterol Clin Biol; 2009; 33(10-11):977-80. PubMed ID: 19765930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.